Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States.

Daniel J George¹, Furaha Kariburyo-Yay², Himani Aggarwal³, Jon G Tepsick², Rebekah Yu², Weiyan Li⁴, Chinelo Orji³, Sameer R Ghate³

¹Duke University, Durham, NC. Electronic address: daniel.george@duke.edu.

²ConcertAI, LLC, Cambridge, MA.

³Merck & Co., Inc., Rahway, NJ.

⁴AstraZeneca, Wilmington, DE.

PubMed DOI

Abstract

INTRODUCTION: The PROfound clinical trial showed that patients with metastatic castration-resistant prostate cancer (mCRPC) who harbored homologous recombination repair gene mutations (HRRm) benefited from receiving olaparib monotherapy. This is the first real-world study in the U.S. to evaluate olaparib monotherapy in patients with mCRPC and HRRm. PATIENTS AND METHODS: This retrospective study u…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.